541 related articles for article (PubMed ID: 29158217)
1. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Escudier M; Cautela J; Malissen N; Ancedy Y; Orabona M; Pinto J; Monestier S; Grob JJ; Scemama U; Jacquier A; Lalevee N; Barraud J; Peyrol M; Laine M; Bonello L; Paganelli F; Cohen A; Barlesi F; Ederhy S; Thuny F
Circulation; 2017 Nov; 136(21):2085-2087. PubMed ID: 29158217
[No Abstract] [Full Text] [Related]
2. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology.
Varricchi G; Galdiero MR; Tocchetti CG
Circulation; 2017 Nov; 136(21):1989-1992. PubMed ID: 29158212
[No Abstract] [Full Text] [Related]
3. Immune checkpoint inhibitors and cardiovascular toxicity.
Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
[TBL] [Abstract][Full Text] [Related]
4. [Research progress on the immune checkpoint inhibitors induced cardiotoxicity].
Lyu SS; Yang YM
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Sep; 47(9):748-751. PubMed ID: 31550849
[TBL] [Abstract][Full Text] [Related]
5. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Guha A; Armanious M; Fradley MG
Trends Cardiovasc Med; 2019 Jan; 29(1):29-39. PubMed ID: 29910109
[TBL] [Abstract][Full Text] [Related]
6. Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Brown SA; Ray JC; Herrmann J
J Cardiovasc Transl Res; 2020 Jun; 13(3):402-416. PubMed ID: 32253744
[TBL] [Abstract][Full Text] [Related]
7. Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer.
Guenancia C; Ladoire S; Ghiringelli F; Rochette L; Vergely C; Cottin Y
Arch Cardiovasc Dis; 2017 Feb; 110(2):69-71. PubMed ID: 28216265
[No Abstract] [Full Text] [Related]
8. Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events.
Reese SW; Marchese M; McNabb-Baltar J
Gastroenterology; 2020 Oct; 159(4):1195-1200.e1. PubMed ID: 32681919
[No Abstract] [Full Text] [Related]
9. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.
Palaskas N; Lopez-Mattei J; Durand JB; Iliescu C; Deswal A
J Am Heart Assoc; 2020 Jan; 9(2):e013757. PubMed ID: 31960755
[No Abstract] [Full Text] [Related]
10. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution.
Anquetil C; Salem JE; Lebrun-Vignes B; Johnson DB; Mammen AL; Stenzel W; Léonard-Louis S; Benveniste O; Moslehi JJ; Allenbach Y
Circulation; 2018 Aug; 138(7):743-745. PubMed ID: 30359135
[No Abstract] [Full Text] [Related]
11. Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature.
Chauhan A; Burkeen G; Houranieh J; Arnold S; Anthony L
Ann Oncol; 2017 Aug; 28(8):2034-2038. PubMed ID: 28472223
[No Abstract] [Full Text] [Related]
12. Cardio-Oncology in 2020: Prime for Translation.
Barac A
J Cardiovasc Transl Res; 2020 Jun; 13(3):345-346. PubMed ID: 32495266
[No Abstract] [Full Text] [Related]
13. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
14. Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors.
Shah C; Gong Y; Szady A; Sun Q; Pepine CJ; Langaee T; Lucas AR; Moreb JS
Cardiovasc Toxicol; 2018 Apr; 18(2):184-191. PubMed ID: 29022233
[TBL] [Abstract][Full Text] [Related]
15. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
Gong IY; Verma S; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Brezden-Masley CB; Gavura S; Peacock S; Chan KK
Breast Cancer Res Treat; 2016 Jun; 157(3):535-44. PubMed ID: 27271767
[TBL] [Abstract][Full Text] [Related]
16. Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.
Brumbaugh AD; Narurkar R; Parikh K; Fanucchi M; Frishman WH
Cardiol Rev; 2019; 27(2):97-107. PubMed ID: 29912044
[TBL] [Abstract][Full Text] [Related]
17. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
[No Abstract] [Full Text] [Related]
18. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
[TBL] [Abstract][Full Text] [Related]
19. Letter by Campochiaro et al Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity".
Campochiaro C; De Luca G; Cavalli G
Circulation; 2018 May; 137(22):2421-2422. PubMed ID: 29844079
[No Abstract] [Full Text] [Related]
20. State of the art review: Chemotherapy-induced cardiotoxicity in children.
Loar RW; Noel CV; Tunuguntla H; Colquitt JL; Pignatelli RH
Congenit Heart Dis; 2018 Jan; 13(1):5-15. PubMed ID: 29226596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
